BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu W, Mao Y, Zhang X, Wang Y, Wu J, Zhao S, Peng S, Zhao M. RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine. Int J Nanomedicine 2019;14:7263-79. [PMID: 31686807 DOI: 10.2147/IJN.S212978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Hawryłkiewicz A, Ptaszyńska N. Gemcitabine Peptide-Based Conjugates and Their Application in Targeted Tumor Therapy. Molecules 2021;26:E364. [PMID: 33445797 DOI: 10.3390/molecules26020364] [Reference Citation Analysis]
2 Li G, Wang T, Zhang X, Zhao S, Wang Y, Wu J, Peng S, Zhao M. Development of 13-Cys-BBR as an Agent Having Dual Action of Anti-Thrombosis and Anti-Inflammation. Drug Des Devel Ther 2020;14:2187-97. [PMID: 32581515 DOI: 10.2147/DDDT.S249228] [Reference Citation Analysis]
3 Qi J, Zeng Z, Chen Z, Nipper C, Liu X, Wan Q, Chen J, Tung C, Zu Y. Aptamer–Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells. Pharmaceuticals 2022;15:558. [DOI: 10.3390/ph15050558] [Reference Citation Analysis]